Shanghai Yifeng Pharmacy Chain Co., Ltd.

A chain pharmacy listed on the main board of China's Shanghai Stock Exchange, stock abbreviation: Yifeng Pharmacy, stock code: 603939
Yifeng Pharmacy Chain Co., Ltd. is a large national pharmaceutical retail chain enterprise (a chain pharmacy listed on the main board of China's Shanghai Stock Exchange), dedicated to the pharmaceutical retail industry for 20 years. Its market value has consistently ranked among the top listed pharmacy chains in China, and it has been rated as one of the Top 500 Listed Companies in China.
As a leader in China's big health industry, Yifeng Pharmacy was founded in June 2001. It has successively expanded into various big health business sectors, including pharmaceutical retail, pharmaceutical wholesale, production and sales of traditional Chinese medicine decoction pieces, chronic disease management, internet hospitals, medical project investment, and medical technology development. As of June 30, 2021, the company achieved total operating revenue of 7.35 billion yuan in the first half of 2021, a year-on-year increase of 16.7%. Currently, the company operates more than 7,000 chain pharmacies in nine provinces and cities, including Hunan, Hubei, Shanghai, Jiangsu, Jiangxi, Zhejiang, Guangdong, Hebei, and Beijing. Among its directly operated stores, 5,011 have obtained various qualifications as "Medical Insurance Designated Retail Pharmacies" (including 706 designated pharmacies for special and chronic disease coordinated medical insurance). The company offers more than 62,000 SKUs, employs over 30,000 staff, and has 46.35 million members.
Since its establishment, the company has always adhered to the core philosophy of "Everything guided by customer value," insisting on customer-centered business model innovation and transformation, providing customers with cost-effective products and professional services for their health. In the future, the company will focus long-term on the pharmaceutical and health industry, aiming to improve the physical and mental health of the Chinese people and become a trustworthy and reliable pharmacy. The company not only emphasizes rapid expansion but also focuses on refined and standardized operational management, establishing six core operating systems covering new store development, store operations, product management, information management, customer service, and performance appraisal, successfully achieving cross-province operations and rapid, efficient replication.
In the future, the company will focus on the pharmaceutical retail industry for the long term, and in the next three years, it will continue to focus on Central and East China, actively expand into the national market, and continuously enhance its core competitiveness through brand image, professional services, product innovation, and business model innovation, striving to become a chain pharmacy that customers trust and society respects.
Since its listing six years ago, the company has maintained a relatively fast growth rate of about 30%, becoming a standout among main board listed companies with its strong operational and profitability capabilities.
"Constantly thinking of your benefit, with virtue and goodness bringing abundance" – In the future, the company will focus on the pharmaceutical and health industry for the long term, aiming to enhance the physical and mental health of the Chinese people and become a trusted and dependable pharmacy.